Magnesium-glycine chelate – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Magnesium glycinate (also called magnesium bisglycinate) is magnesium bound to two glycine molecules. Glycine is also a calming amino acid, and the combination is well tolerated and absorbed without GI side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic mineral

23/100

A well-absorbed magnesium chelate that handles repletion well but offers no genuine research frontier

Look, magnesium glycinate is a better mousetrap for magnesium delivery, not a research frontier. The chelation with glycine solves a real problem: magnesium oxide, the dominant commercial form, has notoriously poor absorption (roughly 4-12% in clinical studies versus approximately 80% for the bisglycinate chelate), which means most people supplementing with oxide are largely supplementing with expensive stools. Glycinate fixes that. That’s genuinely useful, but it’s been understood for decades and doesn’t open a new research question.

The glycine component does add something worth noting. Glycine acts as a co-agonist at the NMDA receptor glycine site, and at doses needed to deliver 200-400 mg elemental magnesium you’re getting roughly 1-2 g glycine per serving, which overlaps with the sleep-promotion literature (Bannai et al., 2012, Frontiers in Neurology). The combination is biologically sensible. But “biologically sensible” isn’t “novel research territory.” Both components are well-characterized independently, and theres no unique pharmacological fingerprint to the chelate that you couldn’t dissect by studying magnesium and glycine separately in a cleaner design.

As a bench tool, magnesium glycinate is weak. Investigators studying NMDA glycine site pharmacology have far more specific probes. Investigators studying magnesium in the CNS would reach for L-threonate, which carries the documented CSF-targeting story out of the Slutsky lab at MIT and a genuinely differentiated mechanistic rationale. The bisglycinate form doesn’t give you precision or resolution you can’t get another way, and the literature treating it as a distinct research compound rather than a delivery vehicle is thin at best.

The differentiation story falls short too. It clearly beats oxide on GI tolerability and elemental yield. But magnesium taurate, malate, and L-threonate are credible comparators for different indications, and glycinate doesn’t dominate the class on any dimension beyond tolerability. That’s useful for compliance studies and population-level repletion trials. It’s not interesting for basic science.

What we’d say plainly: the evidence quality here is reasonable because the underlying magnesium and glycine literatures are large and mature. That’s not a point in favor of glycinate as a research target; it’s evidence the interesting questions in this space have mostly been answered. Repletion in deficient populations? Well-characterized. Novel mechanism, unexplored indication space, surprising biology? Absent. The score reflects a compound that does exactly what it promises, has been doing it for decades, and wont generate findings a bench scientist is going to find worth writing up.

Novelty: 16
Mechanism promise: 22
In-category differentiation: 28
Evidence quality: 32
Translational signal: 22
Research bench value: 15

Rationale Magnesium glycinate improves on oxide meaningfully via bioavailability and adds mild glycine pharmacology at the NMDA co-agonist site, but neither angle constitutes novel research territory; both components are fully characterized independently, there is no unique mechanistic fingerprint to the chelate, and the calculated score of 23 lands well below the generic-mineral ceiling without needing the cap to bind.

Magnesium-glycine chelate

A magnesium chelate with glycine, with superior bioavailability and minimal gastrointestinal effects compared with magnesium oxide.

Abstract

Magnesium glycinate (magnesium bisglycinate) is a chelated magnesium salt where magnesium is bound to two molecules of glycine. The compound has superior bioavailability compared with magnesium oxide (the most common but poorly absorbed form), with absorption rates approaching 80 percent in clinical studies versus 4 to 12 percent for oxide. Glycine has independent anxiolytic and sleep-promoting effects through NMDA glycine site activity. The combination produces a magnesium product with low gastrointestinal disturbance and additional glycine benefits at the dosing required for elemental magnesium repletion. Doses providing 200 to 400 mg elemental magnesium per day are typical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-168Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Magnesium-glycine chelate

Magnesium Glycinate

Abstract

Read the full monograph